€
1. 61
0
0%
€
- Market Cap
- P/E Ratio
- Div Yield
10 Volume
- Eps
€ 1.61
Previous Close Want to track 3F80 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
3F80 closed today higher at €1.61, an increase of 0% from yesterday's close, completing a monthly increase of 0% or €0. Over the past 12 months, 3F80 stock lost -27.2523%.
3F80 is not paying dividends to its shareholders.
Q-linea AB has completed 1 stock splits, with the recent split occurring on Jul 14, 2025.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XMUN (EUR).
3F80 Chart
Q-linea AB (3F80) FAQ
What is the stock price today?
The current price is €1.61.
On which exchange is it traded?
Q-linea AB is listed on XMUN.
What is its stock symbol?
The ticker symbol is 3F80.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Q-linea AB ever had a stock split?
Q-linea AB had 1 splits and the recent split was on Jul 14, 2025.
Q-linea AB Profile
| - Industry | - Sector | Dr. Jonas Jarvius Ph.D. CEO | XMUN Exchange | - ISIN |
| Sweden Country | 97 Employees | - Last Dividend | 14 Jul 2025 Last Split | - IPO Date |
Overview
Q-linea AB (publ) is a prominent company specialized in the development of innovative instruments and consumables tailored for the diagnostics of infections, primarily operating within the United Kingdom. Founded in 2007 and with its headquarters located in Uppsala, Sweden, Q-linea has established itself as a key player in the field. The company primarily focuses on serving healthcare providers by offering cutting-edge solutions for the rapid and accurate diagnosis of infectious diseases, thereby playing a crucial role in improving patient care and treatment outcomes.
Products and Services
- ASTar - An antibiotic susceptibility testing system specifically designed for positive blood cultures. This instrument represents a significant advancement in the field of microbiology and infectious diseases by allowing healthcare providers to quickly determine the most effective antibiotics for treating bloodstream infections. The ASTar system improves the efficiency of antibiotic stewardship programs and supports the fight against antibiotic resistance, thereby ensuring that patients receive the most appropriate and timely antibiotic therapy.
- In Vitro Diagnostics Systems - Specialized systems developed for a broad range of infectious diseases diagnostics. These innovative diagnostic solutions are crafted to meet the demanding needs of modern healthcare settings, providing rapid, accurate, and reliable results. By enabling swift diagnosis, Q-linea's in vitro diagnostics systems play an essential role in ensuring the effective management and treatment of infectious diseases, ultimately contributing to enhanced patient outcomes and public health safety.
Contact Information
Address: Dag HammarskjOelds vAeg 52 A
Phone: 46 1 84 44 36 10
Website: https://qlinea.com
